Enanta Pharmaceuticals (ENTA) FCF Margin (2012 - 2026)

Enanta Pharmaceuticals has reported FCF Margin for 15 years, with the latest figure at 41.79% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin rose 6558.0% year-over-year to 41.79%; the trailing twelve-month figure through Mar 2026 stood at 13.88% (up 11369.0% YoY), and the FY2025 full-year result was 49.24%, up 9375.0% from the prior year.
• FCF Margin for Q1 2026 stood at 41.79%, up from 63.62% in the prior quarter.
• The five-year high for FCF Margin was 149.57% in Q2 2025, with the low at 181.45% in Q2 2023.
• Historically, FCF Margin has averaged 108.31% across 5 years, with a median of 121.33% in 2023.
• Annual changes were most pronounced in 2022 — FCF Margin plunged 11962 bps — and 2025, when it soared 25383 bps.
• Enanta Pharmaceuticals' FCF Margin stood at 164.5% in 2022, then increased by 13 bps to 143.17% in 2023, then retreated by 5 bps to 150.63% in 2024, then soared by 58 bps to 63.62% in 2025, then surged by 34 bps to 41.79% in 2026.
• The last three FCF Margin figures came in at 41.79% (Q1 2026), 63.62% (Q4 2025), and 118.94% (Q3 2025), per Business Quant data.